Pneumococcal disease: cases caused by serotypes not in Prevenar 13 vaccine
Updated 1 May 2026
Applies to England
The number of invasive pneumococcal disease (IPD) cases due to any serotype not covered by Prevenar13™ had been increasing year on year before the COVID-19 pandemic.
In the 2020 to 2021 epidemiological year cumulative case numbers were at their lowest since 2006 in all age groups because of pandemic restrictions.
The cumulative weekly number of cases aged under 2 years to date in 2025 to 2026 up to week 53 was similar to the number observed in the previous epidemiological year (2024 to 2025).
The cumulative weekly number of cases to date among individuals aged between 2 and 64 years was lower than all preceding epidemiological years apart from epidemiological year 2020 to 2021. The number of cases to date among the 65 years and over age group was comparable to numbers observed in previous epidemiological years.
Not PCV13 less than 2 years
Figure 1. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes not covered in Prevenar13™: children aged under 2 years in England, by epidemiological year July to June (2017/2018 to 2025/2026 to date)
For comparison purposes, 58, 79 and 126 cases were reported in 2006/2007, 2009/2010 and 2013/2014 epidemiological years, respectively.
Not PCV13 2 to 4 years
Figure 2. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes not in Prevenar13™: children aged 2 to 4 years in England, by epidemiological year July to June (2017/2018 to 2025/2026 to date)
For comparison purposes, 12, 29 and 63 cases were reported in 2006/2007, 2009/2010 and 2013/2014 epidemiological years, respectively.
Not PCV13 5 to 64 years
Figure 3. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes in not covered in Prevenar13™: persons aged 5 to 64 years in England by epidemiological year July to June (2017/2018 to 2025/2026 to date)
For comparison purposes, 496, 843 and 1,081 cases were reported in 2006/2007, 2009/2010 and 2013/2014 epidemiological years, respectively.
Not PCV13 over 65 years
Figure 4. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes not covered in Prevenar13™: persons aged 65 years and over in England by epidemiological year July to June (2017/2018 to 2025/2026 to date)
For comparison purposes, 466, 966 and 1,394 cases were reported in 2006/2007, 2009/2010 and 2013/2014 epidemiological years, respectively.
The above graphs are based on week of isolation, therefore numbers for the most recent weeks may not be complete. Numbers of reports of serotyped cases shown in the graph are not adjusted to account for any change that may have occurred over time and between age groups in the proportion of all IPD cases that are serotyped.
The 7-valent pneumococcal conjugate vaccine (Prevenar 7) was introduced into the childhood immunisation schedule on 4 September 2006.
The 13-valent pneumococcal conjugate vaccine (Prevenar 13) was introduced into the childhood immunisation schedule on 1 April 2010.
The vaccine schedule for this vaccine changed for infants born on or after January 2020 (with doses given at 12 weeks and 1 year of age (1+1) instead of 8 weeks, 16 weeks and 1 year of age (2+1)).
Source
Immunisation and Vaccine Preventable Diseases Division, UKHSA (formerly Public Health England).